Cannabis for fibromyalgia may reduce pain in seven out of ten patients, according to an Australian trial. The study involved 24 women over a 16-week period, using a sublingual oil with a balanced THC and CBD formulation. The benefits also extended to sleep and quality of life. However, the researchers call for caution before making any broad generalizations.
According to a study published in Pain Research and Management, 24 adults received the oil over a 16-week period. Each millilitre contained 10 mg of THC and 10 mg of CBD. The protocol included four weeks of gradual dose titration, followed by twelve weeks at a stable dose. Each participant took either the product or a placebo once a day, without knowing which group she had been assigned to.
The trial was conducted by three Australian teams from Southern Cross University, Griffith University and Gold Coast University Hospital. The double-blind design confirmed overall satisfactory tolerability. No serious side effects were reported during the 16-week follow-up period. According to the authors, the few adverse effects observed remained mild, mainly drowsiness and slight nausea.
Seven out of ten patients in the treated group achieved at least a 30% reduction in their daily pain score. The placebo reached this threshold in only 20% to 40% of participants, depending on the phase. In addition, 40% of the treated women reported a clear improvement in the overall impact of the disease. The placebo group reached only 10%.
TO CONTINUE READING: Sciences & Vie
TO READ THE STUDY: Pain Research & Management
Chargement en cours...